Iterum Therapeutics plc
ITRM
$0.99
-$0.007-0.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 34.65% | -- | |||
| Gross Profit | -34.65% | -- | |||
| SG&A Expenses | 31.18% | 18.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.09% | -24.90% | |||
| Operating Income | -1.09% | 24.90% | |||
| Income Before Tax | 26.32% | -10.05% | |||
| Income Tax Expenses | 140.00% | -81.62% | |||
| Earnings from Continuing Operations | 25.69% | -8.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.69% | -8.01% | |||
| EBIT | -1.09% | 24.90% | |||
| EBITDA | 1.41% | 30.13% | |||
| EPS Basic | 41.77% | 18.88% | |||
| Normalized Basic EPS | 42.32% | 17.33% | |||
| EPS Diluted | 42.19% | 18.29% | |||
| Normalized Diluted EPS | 42.32% | 17.33% | |||
| Average Basic Shares Outstanding | 27.62% | 33.14% | |||
| Average Diluted Shares Outstanding | 27.62% | 33.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||